Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
Journal of the National Cancer Institute
|
September 28, 2016
Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma
Daniel L Faden, Alain Algazi
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 28, 2025
CRE25-035: Vascular Endothelial Growth Factor Inhibitor-Induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient
Sahithee Alekhya Batchu, Yue Ma, Sue Yom, et al.
Melanoma Research
|
August 22, 2022
Melanoma risk during immunomodulating treatment
Yixuan James Zheng, Wilson Ho, Martina Sanlorenzo, et al.
Cell Reports. Medicine
|
November 8, 2025
Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells
Ravindra Gujar, Chang Cui, Maria Fumagalli, et al.
JAMA Dermatology
|
July 30, 2015
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo, Igor Vujic, Adil Daud, et al.
Journal of the American Academy of Dermatology
|
December 3, 2014
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, et al.
Cancer Biology & Therapy
|
March 22, 2014
Melanoma immunotherapy
Martina Sanlorenzo, Igor Vujic, Christian Posch, et al.
Immunotherapy
|
October 25, 2017
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)
David A Canton, Shawna Shirley, Jocelyn Wright, et al.
The Laryngoscope
|
September 28, 2023
Treatment Modality Impact on Patient-Reported Quality of Life in Human Papilloma Virus-Associated Oropharyngeal Carcinoma
Karolina A Plonowska-Hirschfeld, Arushi Gulati, Erika M Stephens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2017
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
Journal of the National Cancer Institute
|
September 28, 2016
Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma
Daniel L Faden, Alain Algazi
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 28, 2025
CRE25-035: Vascular Endothelial Growth Factor Inhibitor-Induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient
Sahithee Alekhya Batchu, Yue Ma, Sue Yom, et al.
Melanoma Research
|
August 22, 2022
Melanoma risk during immunomodulating treatment
Yixuan James Zheng, Wilson Ho, Martina Sanlorenzo, et al.
Cell Reports. Medicine
|
November 8, 2025
Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells
Ravindra Gujar, Chang Cui, Maria Fumagalli, et al.
JAMA Dermatology
|
July 30, 2015
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo, Igor Vujic, Adil Daud, et al.
Journal of the American Academy of Dermatology
|
December 3, 2014
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, et al.
Cancer Biology & Therapy
|
March 22, 2014
Melanoma immunotherapy
Martina Sanlorenzo, Igor Vujic, Christian Posch, et al.
Immunotherapy
|
October 25, 2017
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)
David A Canton, Shawna Shirley, Jocelyn Wright, et al.
The Laryngoscope
|
September 28, 2023
Treatment Modality Impact on Patient-Reported Quality of Life in Human Papilloma Virus-Associated Oropharyngeal Carcinoma
Karolina A Plonowska-Hirschfeld, Arushi Gulati, Erika M Stephens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2017
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, et al.
Page
of 3